Last reviewed · How we verify
PF-08046044/SGN-35C (pf-08046044-sgn-35c)
PF-08046044/SGN-35C (generic name: pf-08046044-sgn-35c) is a drug developed by Pfizer Inc.. It is currently FDA-approved.
PF-08046044/SGN-35C is a tumor necrosis factor receptor superfamily member 8 agonist, classified as an agonist. It is being studied in clinical trials for various types of cancer, including Hodgkin disease, lymphoma, and large B-cell lymphoma.
At a glance
| Generic name | pf-08046044-sgn-35c |
|---|---|
| Sponsor | Pfizer Inc. |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- PF-08046044/SGN-35C CI brief — competitive landscape report
- PF-08046044/SGN-35C updates RSS · CI watch RSS
- Pfizer Inc. portfolio CI
Frequently asked questions about PF-08046044/SGN-35C
What is PF-08046044/SGN-35C?
Who makes PF-08046044/SGN-35C?
What is the generic name of PF-08046044/SGN-35C?
What development phase is PF-08046044/SGN-35C in?
Related
- Manufacturer: Pfizer Inc. — full pipeline
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing